CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

epacadostat

Small moleculeexperimental

Epacadostat is an investigational drug for cancer. Epacadostat is an inhibitor of indoleamine 2,3-dioxygenase-1 (IDO1). Epacadostat inhibits IDO1 by competitively blocking it, without interfering with IDO2 or tryptophan 2,3-dioxygenase (TDO). It has antitumor activity in some models, though is most effective when combined with other immunotherapy agents. — Wikipedia

Clinical trial activity

59 trials · 40 clinical orgs · 0 marketing orgs

Phase 1
29
Phase 2
47
Phase 3
7
Phase 4
0

Earliest trial started Jul 1, 2010 (NCT01195311)

Timeline

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2012

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2016

    Earliest Phase 3 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

NS(=O)(=O)NCCNc1nonc1/C(=N/O)Nc1ccc(F)c(Br)c1
Mol. weight
438.24 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • epacadostat
  • epacadostat
  • epacadostat
  • epacadostat
  • epacadostat
  • incb024360
  • incb024360
  • incb024360
  • incb-024360
  • incb-024360

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04463771Phase 2Dec 15, 2020European Network for Gynaecological Oncological Trial, GOG Foundation, Inc., Gynecologic Oncology Group, Incyte
NCT04586244Phase 2Dec 15, 2020Incyte
NCT04231864Phase 2Feb 1, 2020AstraZeneca, Incyte, University of California, San Francisco
NCT03832673Phase 2Apr 30, 2019University of Milan
NCT03823131Phase 2Feb 1, 2019Incyte, OncoSec Medical Incorporated, University of California, San Francisco
NCT03491579Phase 1Dec 31, 2018University of Bern
NCT03325465Phase 2Nov 30, 2018University of Chicago
NCT03516708Phase 1/Phase 2 (Phase 2)Oct 31, 2018Incyte, Washington University in St. Louis
NCT03238638Phase 2Sep 30, 2018University of Chicago
NCT03310567Phase 2Sep 30, 2018Temple University
NCT03444649Phase 1Sep 30, 2018University of Bern
NCT03602586Phase 2Sep 28, 2018National Cancer Institute (NCI), NRG Oncology
NCT03402880Phase 2Aug 31, 2018Addario Lung Cancer Medical Institute, City of Hope National Medical Center, Harvard University
NCT03532295Phase 1/Phase 2 (Phase 2)Aug 31, 2018Incyte, Washington University in St. Louis
NCT03432676Phase 2Jul 31, 2018Incyte, Merck, University of Texas at Houston
NCT03589651Phase 1Jul 27, 2018Incyte
NCT03592407Phase 2Jul 1, 2018City of Hope National Medical Center, National Cancer Institute (NCI)
NCT03471286Phase 1May 31, 2018Incyte, Johns Hopkins University
NCT03493945Phase 1/Phase 2 (Phase 2)May 1, 2018National Cancer Institute (NCI)
NCT03463161Phase 2Mar 23, 2018University of Chicago
Showing 20 of 59 trials
Page 1 / 3

Organizations

Research & Development (40)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
IncyteFor profit382532010
MerckFor profit12132014
National Cancer Institute (NCI)Government7322013
Bristol-Myers SquibbFor profit3022014
University of ChicagoAcademic/Hospital3312018
Cancer Immunotherapy Trials NetworkAcademic/Hospital2022013
City of Hope National Medical CenterAcademic/Hospital2212018
Johns Hopkins UniversityAcademic/Hospital2222017
State University of New York, BuffaloAcademic/Hospital2212013
University of BernAcademic/Hospital2212018
University of California, San FranciscoAcademic/Hospital2212019
Washington University in St. LouisAcademic/Hospital2212018
Addario Lung Cancer Medical InstituteAcademic/Hospital1012018
Aduro BioTechFor profit1112016
AstraZenecaFor profit1012020
BriaCell Therapeutics CorporationFor profit1112018
Cancer Insight, LLCFor profit1012018
Columbia UniversityAcademic/Hospital1112018
European Network for Gynaecological Oncological TrialAcademic/Hospital1012020
GenentechFor profit1012014
40 organizations
Page 1 / 2